Screener
Ultragenyx Pharmaceutical RARE Goodwill
Goodwill at other companies
Other financials
Where this comes from
Reported directly by Ultragenyx Pharmaceutical in its filing.
Tagged under the XBRL concept us-gaap:Goodwill.
The source filing: Ultragenyx Pharmaceutical’s 10-Q, filed August 5, 2026.
- Filed
- Aug 4, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333233
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Property, plant, and equipment, net | 235 | 244 |
| Marketable securities | 144 | 57 |
| Intangible assets, net | 172 | 176 |
| Goodwill | 44 | 44 |
| Other assets | 63 | 60 |
| Total assets | $1,264 | $1,532 |
| LIABILITIES, NONCONTROLLING INTEREST AND STOCKHOLDERS' EQUITY (DEFICIT) | ||
| Current liabilities: |
Item 1. Financial Statements
FAQ
- What is Ultragenyx Pharmaceutical's goodwill?
- Ultragenyx Pharmaceutical (RARE) reported goodwill of $44M in Q2 2026.
- How has Ultragenyx Pharmaceutical's goodwill changed year-over-year?
- Ultragenyx Pharmaceutical's goodwill decreased by 0.9% year-over-year, from $44.41M to $44M.
- What is the long-term trend for Ultragenyx Pharmaceutical's goodwill?
- Over 5 years (2020 to 2025), Ultragenyx Pharmaceutical's goodwill has grown at a -0.2% compound annual growth rate (CAGR), from $44.41M to $44M.
- What does goodwill mean?
- The excess of acquisition cost over the fair value of net identifiable assets acquired — representing brand value, customer relationships, and synergies from past M&A.
Ask your AI about Ultragenyx Pharmaceutical's goodwill.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude